| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Other investing activities | 2,150 | - |
| Net cash provided by (used in) investing activities | 473,495 | -27,612 |
| Proceeds from issuance of 0.00 convertible senior notes due 2028, net | 646,372 | - |
| Purchases of capped calls related to 0.00 convertible senior notes due 2028 | 35,311 | - |
| Repayment of 1.00 convertible senior notes due 2027 | 1,102,659 | - |
| Payment of issuance costs for revolving credit agreement | 2,414 | - |
| Proceeds from exercise of stock options and other types of equity, net | 208,327 | 130,587 |
| (repayment of) proceeds from development derivative, net | 64,822 | 32,746 |
| Net cash used in (provided by) financing activities | -350,507 | 97,841 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 40,637 | 41,564 |
| Net increase in cash, cash equivalents and restricted cash | 524,150 | 147,209 |
| Cash and cash equivalents at beginning of period | 968,652 | - |
| Cash and cash equivalents at end of period | 1,492,802 | - |
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)